Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

60.42 -0.58 (-0.95%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Exploring the top movers within the S&P500 index during today's session. ↗
Via Chartmill
News headline image
Moderna-Arbutus-Genevant Patent Settlement: Wall Street Says Not Best-Case Scenario But Removes Overhang For MRNA Stock ↗
The news is likely to come as a relief to many investors, Citi told investors in a research note. 
Via Stocktwits
Topics Intellectual Property
Discover which S&P500 stocks are making waves on Wednesday. ↗
Via Chartmill
News headline image
2 High-Flying Stocks With More Upside to Buy and Hold ↗
It's not too late to get in on the action. 
Via The Motley Fool
Topics Artificial Intelligence Supply Chain
Get insights into the top movers in the S&P500 index of Wednesday's pre-market session. ↗
Via Chartmill
News headline image
MSTR, CRWD, MRNA, GTLB On Traders' Radar Today — Dow Futures Edge Higher As Investors Look Past Middle East Conflict ↗
Following warnings from Iran over the closure of the Strait of Hormuz, President Donald Trump announced that the U.S. would extend risk insurance for maritime trade through the strait. 
Via Stocktwits
Topics ETFs Government Intellectual Property
These stocks are moving in today's after hours session ↗
Via Chartmill
News headline image
MRNA Shares Rally After Hours On Inking Settlement Deal Over Vaccine Patent Row ↗
The settlement resolves all enforcement actions involving Moderna’s use of Genevant’s and Arbutus’ LNP delivery technology in its COVID-19 vaccines. 
Via Stocktwits
Topics Intellectual Property
News headline image
Moderna Resolves Global Patent Litigation with Arbutus/Genevant
Via ACCESS Newswire
Exploring the top movers within the S&P500 index during today's session. ↗
Via Chartmill
News headline image
Moderna Stock (MRNA): Is It a Buy Now? 7 Questions After the Crash ↗
Moderna stock has crashed 90% — but is the market mispricing what comes next? 7 key questions on MRNA's cancer vaccine, cash runway, and upside case. 
Via InvestorPlace
News headline image
The Great Pivot: Inside Novavax’s 2026 Turnaround and the Road to Combination Vaccines
As of today, February 27, 2026, the biotech sector is witnessing a dramatic reappraisal of one of its most storied pandemic-era players. Novavax (NASDAQ: NVAX) has surged 17.4% following the release of... 
Via Finterra
Topics Economy
News headline image
European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19
Via ACCESS Newswire
News headline image
Moderna's Ups and Downs: Here's What You Need to Know Before Investing. ↗
The stock, after a few tough years, soared in the double-digits in January. 
Via The Motley Fool
News headline image
3 Reasons to Avoid MRNA and 1 Stock to Buy Instead
What a fantastic six months it’s been for Moderna. Shares of the company have skyrocketed 99.8%, hitting $50.65. This was partly due to its solid quarterly results, and the run-up might have investors... 
Via StockStory
News headline image
Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board
From Tectonic Therapeutic
Via GlobeNewswire
News headline image
Moderna Stock Is Trading Higher Today: What's Going On? ↗
Moderna Inc (NASDAQ:MRNA) shares are trading higher on Monday. Piper Sandler boosted its price target on the stock to $69 from $63 while reiterating an Overweight rating. 
Via Benzinga
News headline image
Here's Why I Wouldn't Touch Moderna With a 10‑Foot Pole Until Its Next Growth Engine Is Clear ↗
Moderna made a fortune with COVID vaccines, but revenue has since declined. 
Via The Motley Fool
News headline image
Billionaire Philippe Laffont Just Dumped CoreWeave and Opened a Position in a Stock That Soared Nearly 50% in January. ↗
Laffont's new addition may represent an exciting recovery story. 
Via The Motley Fool
Topics Artificial Intelligence
Friday's session: gap up and gap down stock in the S&P500 index ↗
Via Chartmill
News headline image
Moderna’s Q4 Earnings Call: Our Top 5 Analyst Questions
Moderna’s fourth quarter results were received positively by the market, reflecting a combination of better-than-expected revenue and effective cost management. Management cited the successful U.S.... 
Via StockStory
Topics Earnings
Uncover the latest developments among S&P500 stocks in today's session. ↗
Via Chartmill
News headline image
Moderna to Present at Upcoming Conferences in March 2026
Via ACCESS Newswire
News headline image
3 Once-in-a-Decade Buying Opportunities ↗
Bargain-hunters should give these stocks a close look. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Why Moderna (MRNA) Stock Is Trading Up Today
Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 5.9% in the afternoon session after the U.S. Food and Drug Administration (FDA) reversed an earlier decision and agreed to review the... 
Via StockStory
Topics Economy
These S&P500 stocks are moving in today's session ↗
Via Chartmill
News headline image
Why Moderna Stock Just Popped ↗
So the FDA will consider Moderna's flu vaccine application after all. Does this make Moderna stock a buy? 
Via The Motley Fool
Wednesday's session: gap up and gap down stock in the S&P500 index ↗
Via Chartmill
News headline image
Moderna Stock Gains After FDA Accepts Company’s Revised Flu Vaccine Application For Review ↗
The FDA has now accepted the biologics license application for review, setting a Prescription Drug User Fee Act goal date of Aug. 5, 2026. 
Via Stocktwits
What's going on in today's pre-market session: S&P500 movers ↗
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.